A PYMNTS Company

HSR waiting period expires for Bristol-Myers Squibb’s tender offer for Inhibitex

By  |  February 3, 2012
HSR waiting period expires for Bristol-Myers Squibb’s tender offer for Inhibitex

Bristol-Myers Squibb has announced that the Hart-Scott-Rodino waiting period has expired for its cash tender offer to purchase all outstanding shares of common stock of Inhibitex. Inhibitex is a drug maker that develops drugs for treating hepatitis C. The tender offer will expire at midnight EST on February 10.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Source: MarketWatch

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source